Stratifies bleeding risk after NSTEMI.
- Risks and benefits of anti-thrombotic therapy and invasive treatment should be carefully considered in ALL patients presenting with NSTEMI or STEMI.
- The CRUSADE bleeding risk score may have decreased utility in NSTEMI patients who receive 2 or more anti-thrombotic agents but do not undergo PCI.
- Alternative bleeding risk scores may also be utilized in certain groups of patients.
- Consider less invasive or high-risk anti-thrombotic dosage protocols in those STEMI/NSTEMI patients with increased risk for bleeding based on the CRUSADE bleeding risk score.